INOZYME PHARMA, INC. Deferred Tax Assets, in Process Research and Development
INOZYME PHARMA, INC. had Deferred Tax Assets, in Process Research and Development of $37.67 million as of 2024-12-31, per its 10-K filed 2025-03-10.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2025-03-10
- 2024-12-31: Deferred Tax Assets, in Process Research and Development $37.67M.
- 2023-12-31: Deferred Tax Assets, in Process Research and Development $21.96M.
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $10.47M.
- 2021-12-31: Deferred Tax Assets, in Process Research and Development $0.00.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2024-12-31 | $37.67M 10-K · filed 2025-03-10 |
| 2023-12-31 | $21.96M 10-K · filed 2025-03-10 |
| 2022-12-31 | $10.47M 10-K · filed 2024-03-12 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-22 |